RE:RE:RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024Impending patents cliffs will be a big motivator for deals, according to Cantor, who also stated that over the next 4 years, approximately US$182 Billion in revenue is at risk, with oncology products accounting for 42% of that number. Meanwhile, the global market for oncology drugs is expected to grow at of unparalled rate of over 75% to US$323 Billion in 2028.